PNV - Banter and General Comments, page-12447

In the latest presentation they have crossed out “Next Generation” and wrote in “New standard of care”

Don’t think they can write that if their largest market which is the US they are not the Standard of care. If so that is quite misleading.

Standard of care means best option for the price. My understanding is that it is also a better product according to all the papers and reports I have read regardless of price. So in theory they could increase their revenue by 30-50% instantly and still be cheaper.

I think this is a good way to go as growth of revenue is key here, seem quiet slow on the R&D and entry into new markets.

Kerecis fish skin product was mainly sold in the US and sold a similar amount of product before it was bought out as Polynovo in the US only.

I get this is different but I think a decent price rise is justified especially in the US. Potential tarrifs or price caps could be on the horizon according to Trumpy.